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OUTCOMES OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYNDROME
Parikh, S.H., Martin, P.L., Szabolcs, P., Ann, S., Prasad, V., Driscoll, T.,
Kurtzberg, J. Duke University Medical Center, Durham, NC.
Myelodysplastic syndromes (MDS) in children are associated
with signiﬁcant risk of leukemic transformation. Allogeneic stem
cell transplantation is the only cure. Many patients do not have a
suitable donor. Between 1995 and 2004, we transplanted 30 chil-
dren lacking matched living stem cell donors with unrelated um-
bilical cord blood (UCB). The M:F ratio of the patients was 1.
Nine patients belonged to ethnic minorities (30%), median age was
9.06 years (range, 1.36–16.83 years), and median weight was 28.4
kg (range, 8.3–62.6 kg). Eight patients had secondary MDS (3
Kostmann’s, 1 Shwachman-Diamond, 3 post-ALL, and 1 post-
neuroblastoma therapy). Ten patients had bone marrow blasts 
20% pretransplantation (8 of 22 with primary MDS and 2 of 8 with
secondary MDS). The preparative regimen was TBI-based in 19
patients and chemotherapy-based in 11 patients. Cyclosporine and
solumedrol were used for GVHD prophylaxis. Grafts were
matched at HLA class I (A,B) at the serologic level and at class II
(DRB1) at the allelic level. Grafts matched at 5/6 HLA loci in 8
patients, 4/6 HLA loci in 21 patients, and 3/6 HLA loci in 1
patient. Grafts delivered a median of 4.12  107 (range, 1.68–
29.16) nucleated cells/kg precryopreservation. Median CD34 cell
dose infused postthaw was 1.48  105/kg (range, 0.17–28.46).
Twenty-four of 30 patients (80%) engrafted with donor cells. Of
the engrafting patients, median time to ANC  500/L was 24
days (range, 6–48 days), and median time to platelet recovery
(platelets  50K untransfused) of evaluable patients was 72 days
(range, 41–137 days). Acute GVHD grade III-IV occured in 5
patients, all of whom had gut involvement. Limited chronic
GVHD was seen in 4 patients. Fifteen patients died, 5 of infections
(1 of pseudomonas, 1 of toxoplasmosis, 1 of aspergillosis, 2 of
EBV), 3 of graft failure, 2 of GVHD, 2 of relapse, 1 of pulmonary
hemorrhage, 1 of CNS hemorrhage, and 1 of MSOF. Fifteen
patients (50%) are surviving in remission from 3.4 to 107 months
(median, 50 months) posttransplantation. Thirteen of 20 patients
(65%) with &le: 20% blasts pretransplantation are alive disease-
free, whereas only 1 of 10 (10%) patients with  20% blasts is
alive. Six of 8 children with secondary MDS (75%) are alive,
compared with 13 of 22 (40%) with primary MDS, possibly due to
the greater number of patients with  20% blasts in the latter
group. These results, especially in patients with  20% blasts
pretransplantation, are equivalent to matched allogeneic bone mar-
row transplantation data. We conclude that unrelated UCB donors
should be actively considered for pediatric patients with MDS who
lack a living related or unrelated stem cell donor to enable trans-
plantation when the blast counts are low.
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RISK FACTORS FOR LIVER DYSFUNCTION IN PEDIATRIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HSCT) RECIPIENTS
Subba Rao, G., Molleston, J., Gowan, D., Haut, P.R. Riley Childrens
Hospital, Indiana University, Indianapolis, IN.
Background: Liver dysfunction (LD), inlcuding veno-occlusive
disease (VOD), is common following HSCT. Though there are a
number of studies in adults on LD following HSCT, data from
children are limited. The aim of this study was to characterize LD
in pediatric HSCT recipients during the initial 100 days follwing
HSCT.Methods: A retrospective analysis of patients under age 21
years who had undergone HSCT over a 4-year period (July 1999-
June 2003) was conducted. LD was deﬁned as the presence of
clinical jaundice and/or elevated ALT/GGT(1.5 times normal).
Results: A total of 58 patients underwent HSCT (25 allogeneic)
during the study period (34 males; mean age, 7.3  6.1 years). The
underlying conditions included acute lymphocytic leukemia (9
cases), acute myelocytic leukemia (16 cases), lymphoma (7 cases),
and solid tumors (26 cases). LD was seen in 47 (81%) patients. LD
was caused by VOD[VOD] in 12.8%, graft- versus-host disease in
14.9%, sepsis in 2.8%, viral hepatitis in 2.1%, drugs in 8.9%,
underlying disease in 3.3%, biliary disease in 3.3%, and indeter-
minate cause in 9.6%, and was multifactorial in 42.3%. Patients
with LD had mean peak ALT values of 243  287 U/L), mean
peak GGT values of 389  576 U/L, and mean peak bilirubin
values of 5.1  8.5 mg/dL. There was no signiﬁcant difference in
LD between autologous and allogeneic HSCT recipients, or be-
tween those with HLA mismatch and perfect match (P  .2).
There was no difference in conditioning regimen GVHD prophy-
laxis between patients with LD and without LD (P  .2). Patients
who developed LD received parenteral nutrition for signiﬁcantly
longer periods (39 days vs 22 days; P  .02) and had a higher
pretransplantation ALT (52 vs 23; P  .009) and GGT (69 vs 26;
P  .02) compared to those without LD. Patients who received
amphotericin B during the posttransplantation period had a higher
chance of developing LD (P  .05). Twleve patients died in the
initial 100 days; 3 had VOD. Total bilirubin was signiﬁcantly
elevated in those who died compared to survivors (median, 2.7
mg/dL [range, 0.6–34] vs median, 1 mg/dL [range, 0.3–10]; P 
.02). Conclusion: LD was a frequent occurrence in patients in this
study. The majority of LD was multifactorial in etiology. Devel-
opment of LD was not related to stem cell source or to condition-
ing regimen. LD was more likely to occur in those with elevated
pretransplantation ALT and/or GGT. The risk of developing LD
was greater in those who received amphotericin B and those who
received prolonged parenteral nutrition. LD contributes signiﬁ-
cantly to the morbidity and mortality in post-HSCT recipients.
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NONMYELOABLATIVE CONDITIONING WITH 200 CGY TOTAL BODY
IRRADIATION (TBI) PRIOR TO MATCHED LITTERMATE ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN DOGS
WITH CANINE LEUKOCYTE ADHESION DEFICIENCY RESULTS IN
HIGHER LEVELS OF ENGRAFTMENT AND DONOR CHIMERISM COM-
PARED TO BUSULFAN ALONE
Sokolic, R.A.1, Burkholder, T.2, Tuschong, L.M.1, Bacher, J.2,
Hai, M.1, Gu, Y.-C.1, Bauer, T.R.1, Hickstein, D.D.1 1Experimental
Transplantation and Immunology Branch, National Cancer Institute,
Bethesda, MD; 2Division of Veterinary Resources, National Institutes of
Health, Bethesda, MD.
Leukocyte adhesion deﬁciency (LAD) is due to defects in the inte-
grin CD18 and results in a syndrome of severe, recurrent bacterial
infections as a result of the failure of leukocytes to adhere to endo-
thelium and migrate to sites of infection. Approximately 75% of
children with severe deﬁciency LAD die by age 2 years. Allogeneic
HSCT after myeloablative conditioning has been shown to cure
LAD; however, regimen-related toxicity (RRT) and graft-versus-host
disease (GvHD) have restricted the use of this approach. We used
dogs with canine leukocyte adhesion deﬁciency (CLAD), which
closely resembles severe deﬁciency LAD, to test nonmyeloablative
transplantation approaches before their use in human LAD.
CLAD pups, identiﬁed by the absence of CD18 on their leuko-
cytes, were DLA-typed using microsatellite repeats closely linked
to the DLA class I and II loci. Six pups were given 200 cGy TBI,
followed by 8.4  1.2 (mean  SEM) CD34 cells/kg from
matched littermates. Three pups were given 10 mg/kg busulfan
intravenously, followed 2 days later by 12.0  2.5  106 CD34
cells/kg. Posttransplantation immunosuppression with cyclospor-
ine A and mycophenolate mofetil was used in both groups. Dogs
were observed for evidence of infection, regimen-related toxicity
(RRT), GvHD, and overall health. Chimerism was assessed by ﬂow
cytometry for CD18. Three dogs lacking a matched littermate died
from infection before 6 months of age.
All of the TBI-treated animals and 2 of the 3 busulfan-treated
dogs engrafted. In the TBI cohort, donor chimerism at 1 year
averaged 34%  8.6% and continues to rise. In the busulfan
cohort, donor chimerism at 6 months averaged 16%  7.6%, with
chimerism peaking at 4 months posttransplantation. There was no
RRT or GvHD in either group.
Because TBI in children is associated with growth suppression,
sterility, and increased cancer risk, a non-TBI regimen before HSCT
has important advantages. The busulfan regimen used here allowed
for sufﬁcient chimerism to reverse the CLAD phenotype in 2 of 3
dogs. More intensive conditioning and/or immunosuppression, or
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